Perrigo posts $1.3 billion goodwill impairment; FY2026 adjusted EPS outlook $2.00-$2.30
Perrigo reported fourth-quarter 2025 net sales of $1.11 billion, down 2.5% year over year, and a reported net loss of $1.41 billion, or $(10.20) per share, driven mainly by a $1.3 billion goodwill impairment. Adjusted EPS fell to $0.77 from $0.93, and the company's FY2026 'All In' adjusted diluted EPS outlook of $2.00 to $2.30 is below the FY2025 adjusted EPS of $2.75.
Key points
- Q4 2025 net sales were $1.11 billion, down 2.5%; organic net sales fell 4.5%, with infant formula a key drag.
- Reported Q4 EPS was $(10.20) versus $(0.30) a year earlier, due primarily to the $1.3 billion goodwill impairment.
- FY2026 'All In' net sales outlook is -5.5% to -1.5%; the 'CORE' adjusted EPS outlook is $2.25 to $2.55 versus FY2025 CORE adjusted EPS of $2.52.
- The company plans a two-year operational enhancement program with about 7% workforce reduction and $80 million to $100 million in pre-tax annualized savings by the end of FY2027.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.